TACC3 and cervical carcinoma: Therefore, we planned to discover and validate the presence of therapeutically targetable events such as FGFR3-TACC3 fusion in cervical cancer using datasets from two large cervical cancer patient cohorts, and then to clarify the use of the fusion product as a therapeutic target, leading to the development of new therapeutic strategies for cervical cancer.